Heart Failure
Conditions
Interventions
Case series:None
Sponsors
Beijing Anzhen Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adult patients over 18 years old; 2. NYHA cardiac function classification: II-IV; 3. LVEF 50%); 4. Patients who meet the conditions required in other treatment standards of sacubitril valsartan sodium tablets and will start the treatment of sacubitril valsartan sodium tablets: diastolic blood pressure >= 100 mmHg, eGFR >= 30 mL/min/1.73 m2; Potassium ion <= 5.2mmol/l; 5. The patient had no ARNI medication history in the past, and the clinic believed that it was necessary to take routine triple or quadruple ARNI+MRA for heart failure during this visit+ ß- Blocker SGLT2 inhibitor). (Within 2 weeks of this administration, it is regarded as the baseline); 6. Patients who signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Allergic or contraindicated to the study drug or drugs such as ACEi, ARBs, and NEPi; 2. No history of angioedema (including drug-induced and others); 3. Those who plan to take left ventricular assist or CRT and other instruments in the past three months; 4. Those who are under the treatment of ACEi, nesiritide, aliskiren, or other drugs that affect the absorption of the test drug of this drug; 5. Those who are undergoing or have ever been treated with sacubitril valsartan sodium tablets; 6. Insufficient elution of nonstudy drugs before the start of the study (ACEi users need at least 36 hours of elution); 7. Enrolled in other clinical trials 30 days before the start of the experiment; 8. History of metastatic cancers within 1 year; 9. Pregnant, breastfeeding or non-contraceptive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BNP;NT-proBNP;sST2;cTnI;cTnT;D-Dimer;NGAL;ANP;proBNP;ACE2;TNF-a; | — |
Countries
China
Contacts
Public ContactYuan Hui
Beijing Anzhen Hospital
Outcome results
None listed